Evidence map›Paper›PMID 21374085›Full record

ArticleClinical & experimental metastasis2011

Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.

Wei Bin Fang, Iman Jokar, Anna Chytil, Harold L Moses, Ty Abel, Nikki Cheng

Abstract read
In one paragraph

Article in Clinical & experimental metastasis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. TGF-β: duality of function between tumor prevention and carcinogenesis.Journal of the National Cancer Institute · 2014
    Review
  20. Fibroblasts as architects of cancer pathogenesis.Biochimica et biophysica acta · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Wei Bin FangDepartment of Pathology and Laboratory Medicine, University of Kansas Cancer Center, Kansas City, 66160, USA.
Iman Jokar
Anna Chytil
Harold L Moses
Ty Abel
Nikki Cheng
University of Kansas · USThe University of Kansas Cancer Center · USVanderbilt-Ingram Cancer CenterVanderbilt University · USVanderbilt University Medical Center · US

Funding

TGF BETA SUPPRESSION AND PROMOTION OF MAMMARY CARCINOMASR01CA085492 · NCI · VANDERBILT UNIVERSITY · PI MOSES, HAROLD L, WEAVER, VALERIE MARIE · 2000 to 2015
$6.4M
TGF-beta in Mammary Development and TumorigenesisR01CA102162 · NCI · VANDERBILT UNIVERSITY · PI MOSES, HAROLD L · 2003 to 2013
$4.5M
Functions of chemokine and TGF-B signaling in the breast cancer microenvironmentR00CA127357 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI CHENG, NIKKI · 2010 to 2012
$732k
Functions of chemokine and TGF-B signaling in the breast cancer microenvironmentK99CA127357 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI CHENG, NIKKI · 2008 to 2009
$298k
NCI NIH HHS CA102162NCI NIH HHS CA127357-01A2NCI NIH HHS CA85492NCI NIH HHS K99 CA127357NCI NIH HHS R00 CA127357NCI NIH HHS R01 CA085492NCI NIH HHS R01 CA102162
6 · The paper itself

Abstract

Accumulation of fibroblasts is a phenomenon that significantly correlates with formation of aggressive cancers. While studies have shown that the TGF-β signaling pathway is an important regulator of fibroblast activation, the functional contribution of TGF-β signaling in fibroblasts during multi-step tumor progression remains largely unclear. In previous studies, we used a sub-renal capsule transplantation model to demonstrate that homozygous knockout of the Tgfbr2 gene (Tgbr2(FspKO)) enhanced mammary tumor growth and metastasis. Here, we show for the first time a significant role for loss of one Tgfbr2 allele during multi-step mammary tumor progression. Heterozygous deletion of Tgfbr2 in stromal cells in MMTV-PyVmT transgenic mice (PyVmT/Tgfbr2(hetFspKO) mice) resulted in earlier tumor formation and increased stromal cell accumulation. In contrast to previous studies of Tgbr2(FspKO) fibroblasts, Tgfbr2(hetFspKO) fibroblasts did not significantly increase tumor growth, but enhanced lung metastasis in PyVmT transgenic mice and in co-transplantation studies with PyVmT mammary carcinoma cells. Furthermore, Tgfbr2(hetFspKO) fibroblasts enhanced mammary carcinoma cell invasiveness associated with expression of inflammatory cytokines including CXCL12 and CCL2. Analyses of Tgbr2(FspKO) and Tgfbr2(hetFspKO) fibroblasts revealed differences in the expression of factors associated with metastatic spread, indicating potential differences in the mechanism of action between homozygous and heterozygous deletion of Tgfbr2 in stromal cells. In summary, these studies demonstrate for the first time that loss of one Tgfbr2 allele in fibroblasts enhances mammary metastases in a multi-step model of tumor progression, and demonstrate the importance of clarifying the functional contribution of genetic alterations in stromal cells in breast cancer progression.

Indexed as

Neoplasm MetastasisAllelesAnimalsAntigens, Polyomavirus TransformingDisease Models, AnimalDisease ProgressionFemaleFibroblastsMaleMammary Neoplasms, AnimalMammary Tumor Virus, MouseMiceMice, NudeMice, TransgenicProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaAntigens, Polyomavirus TransformingProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type II

Identifiers

PMID21374085
PMCPMC3373018
OpenAlexW1978580798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.